Granuloma annulare (GA) is a granulomatous, idiopathic, inflammatory skin disorder characterized by the formation of papules and plaques with annular and acral distribution.1 GA is often limited and self-resolving, but in some cases, it can be generalized and refractory to treatments.1 New advances in the pathophysiology of GA have favoured Janus kinase (JAK) inhibitors as a promising therapeutic option.1,2 Here, we report three cases of resistant generalized GA successfully treated with tofacitinib. Further studies are necessary to assess the safety and the long-term remission of GA patients treated with tofacitinib, and to study the efficacy of other JAK inhibitors in these patients. In addition, other JAK inhibitors such as baricitinib and upadacitinib have recently been used in two generalized GA patients with good results.7,8 In conclusion, advances in GA pathophysiology have allowed the introduction of JAK inhibitors as a new treatment option. [Extracted from the article]